Role of metalloproteinases in platelet function

María José Santos-Martínez1, Carlos Medina, Paul Jurasz

  • 1School of Pharmacy and Pharmaceutical Sciences Trinity College Dublin, Ireland.

Thrombosis Research
|August 8, 2007
PubMed

Insights

Platelets release matrix metalloproteinases (MMPs), their inhibitors (TIMPs), and disintegrin metalloproteinases (ADAMs) that regulate platelet functions like adhesion, aggregation, and interactions with tumor cells and leukocytes.

Area of Science:

  • Biochemistry
  • Hematology
  • Molecular Biology

Background:

  • Platelets are crucial in hemostasis and thrombosis.
  • Platelets contain and release various proteases, including matrix metalloproteinases (MMPs), their inhibitors (TIMPs), and disintegrin metalloproteinases (ADAMs).
  • These platelet-derived proteins play roles beyond coagulation, influencing cellular interactions and disease processes.

Purpose of the Study:

  • To review the diverse roles of MMPs, TIMPs, and ADAMs within platelets.
  • To elucidate the mechanisms by which these proteases regulate platelet functions.
  • To highlight the significance of platelet-associated proteases in physiological and pathological contexts.

Main Methods:

  • Literature review focusing on platelet proteases.
  • Analysis of existing research on MMPs, TIMPs, and ADAMs in platelet biology.
  • Synthesis of findings regarding the functional impact of these proteins on platelet activities.

Main Results:

  • Platelets express a repertoire of MMPs (e.g., MMP-1, MMP-2, MMP-3, MMP-9, MT1-MMP/MMP-14), TIMPs (TIMP-1, TIMP-2, TIMP-4), and ADAMs (ADAM-10, ADAM-17, ADAMTS-13).
  • These proteins modulate key platelet functions, including agonist-stimulated adhesion and aggregation.
  • They are involved in complex interactions such as tumor cell-induced platelet aggregation and platelet-leukocyte aggregation.

Conclusions:

  • Platelet proteases (MMPs, TIMPs, ADAMs) are integral to platelet function regulation.
  • These proteins mediate critical cellular interactions, impacting thrombosis, inflammation, and cancer metastasis.
  • Understanding these mechanisms offers insights into potential therapeutic targets.

Related Concept Videos

Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Role of Matrix Metalloproteases in Degradation of ECM01:23

Role of Matrix Metalloproteases in Degradation of ECM

Matrix metalloproteases (MMPs) are enzymes involved in the hydrolysis of proteins and glycoproteins of the extracellular matrix. MMPs are essential for the migration and proliferation of cells through the dense matrix network, throughout embryonic development, and throughout morphogenesis. The first MMP activity discovered was a collagenase in a tadpole's tail undergoing metamorphosis. The active collagen deposition and modifications lead to the morphogenesis of tadpoles into the adult body.
A...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...